Mounjaro 7.5mg: reaching the middle of the schedule

Picture yourself the morning after your first 7.5mg injection

The pen looks identical to the 5mg one. The injection technique is the same. What changes is what happens over the next few days: some people notice a renewed wave of nausea that had mostly settled, others feel very little difference from 5mg, and some find appetite drops more noticeably than it did at any earlier step. All three experiences are reported, and all three are within normal range.

A misconception that comes up regularly is that a stronger dose means faster weight loss in a simple, linear way. It doesn't quite work like that. What higher doses do is sustain the dual GIP and GLP-1 receptor activation that drives Mounjaro's effect (the fuller signal, the slower gastric emptying, the steadier appetite reduction) at a level that many people find more effective than 5mg. Whether that translates to meaningfully more weight loss for any given individual is something only time and clinical review can confirm.

The tirzepatide overview on this site goes into the receptor mechanism in more detail if the biology interests you. The short version: 7.5mg is where the therapeutic effect tends to become more established for a larger share of patients, rather than merely settling the body in as 2.5mg does.

How the 7.5mg step fits into the titration schedule

Mounjaro's UK licensed schedule runs from 2.5mg up to 15mg across six steps, and if you want to understand how Mounjaro works across the full titration journey, that overview covers each stage in detail. The standard cadence is one step roughly every four weeks, though the Mounjaro patient information leaflet is the definitive reference for titration timing, not a forum post or a peer's experience. Reaching 7.5mg typically means at least eight weeks of treatment have passed since starting.

The prescriber's job at each review is to weigh up tolerability against effect. If nausea at 5mg was significant and only recently settled, staying there longer before moving up is clinically reasonable. If 5mg was comfortable and early results are modest, 7.5mg is the logical next conversation. Neither outcome is a failure, titration is an individualised process, not a race to the highest number.

People sometimes ask whether they can stay at 7.5mg indefinitely rather than continue climbing. The answer depends on the individual: if a person is reaching their weight-management goals at this dose and tolerating it well, a prescriber may see no reason to increase. The licensed doses above 7.5mg exist because many people need them, not because every patient must reach 15mg. This is exactly the kind of question worth raising at your clinical review, and something our prescribers work through with patients regularly. See the frequently asked questions page for more on how review conversations work.

Side effects specific to a dose increase at this stage

The pattern at 7.5mg echoes what happens at every step-up: the body has adjusted to the previous dose, and the new one can temporarily reset that. Nausea is the most commonly reported effect, followed by loose stools, constipation (sometimes alternating with diarrhoea), and a general feeling of fullness that can make eating feel effortful. Most of this settles within days to a couple of weeks as the body acclimates.

The NHS tirzepatide medicines page lists the full side-effect profile clearly. One thing worth flagging: severe, persistent stomach pain that spreads toward the back is not routine nausea and warrants urgent medical attention. The MHRA highlighted acute pancreatitis as an infrequent but serious risk across GLP-1 medicines in a 2026 Drug Safety Update, any doubt, get seen the same day.

Injection-site reactions are also possible: mild redness, itching or a small lump at the site. Rotating between the abdomen, thigh and upper arm from one injection to the next reduces this. Storage stays the same at every dose, refrigerated between 2 and 8°C, with a limited window at room temperature that the patient information leaflet specifies exactly.

Anyone who has had a difficult few weeks on Mounjaro will find the experience around week seven addressed in more depth elsewhere on this site.

Eligibility and cost context at this stage in treatment

Reaching 7.5mg means you were already assessed as suitable for Mounjaro and have been titrating through the schedule. The private eligibility criteria (adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition) applied at the outset. What changes at each repeat order is the clinical review: a named prescriber re-assesses before every further supply, checking progress, tolerability and any new health information.

On the NHS, Mounjaro access through primary care is being phased in gradually under NICE guidance TA1026, with strict eligibility thresholds that don't yet cover everyone who qualifies privately. For people who don't meet the current NHS criteria or prefer not to wait, a regulated private route is the practical alternative.

The cost of treatment rises through the dose schedule because higher-strength pens carry a higher list price, and reading about what the Mounjaro 5mg step involves can help you understand where the pricing journey begins before committing to a long-term plan. The Mounjaro cost guide sets out the UK pricing landscape honestly, including what changed after Eli Lilly revised list prices in September 2025. At every dose, a legitimate private supply requires a prescription from a regulated prescriber; any seller offering these medicines otherwise is a red flag, not a bargain.

If you're approaching a review and want to speak with a prescriber about moving to 7.5mg or staying where you are, the starting point is a clinical assessment that looks at the whole picture. Speak to our prescribers and we'll review your case the same day.